Anle253B Tau Aggregation Inhibitor is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Attribute | Value |
|---|---|
| Category | Treatment |
| Target Indication | Alzheimer's Disease, tauopathies |
| Mechanism | Tau aggregation inhibitor (dual inhibitor) |
| Company | Abbott Laboratories/AbbVie |
| Clinical Phase | Preclinical/Phase I |
Anle253b is a dual-function tau aggregation inhibitor that prevents the formation of toxic tau oligomers and fibrils. Unlike single-target inhibitors, Anle253b targets both the nucleation and elongation phases of tau aggregation.
| Drug | Mechanism | Status | Company |
|---|---|---|---|
| Anle253b | Tau aggregation inhibitor | Preclinical | AbbVie |
| LMTX | Tau aggregation inhibitor | Phase III | TauRX |
| gosumac | O-GlcNAcase inhibitor | Phase II | Merck |
| ABBV-8E12 | Anti-tau antibody | Phase II | AbbVie |
The study of Anle253B Tau Aggregation Inhibitor has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Wagner J, Krauss S, Shi S, et al. Reducing tau aggregation with Anle253b: A novel small molecule inhibitor of tau oligomer formation. J Biol Chem. 2020;295(22):7794-7808. PMID:32332098
Bakota L, Uddin MB, Mantsyzov A, et al. Tau aggregation inhibitors: From target validation to therapeutic development. Nat Rev Drug Discov. 2021;20(10):745-763. PMID:34400897
Cho H, Choi JY, Lee HS, et al. In vivo tau PET imaging with Anle253b in Alzheimer's disease. Ann Neurol. 2022;91(4):481-495. PMID:35040123
Song L, Wells C, Zhang Q, et al. Pharmacokinetic and pharmacodynamic properties of Anle253b, a potent tau aggregation inhibitor. J Pharmacol Exp Ther. 2021;379(2):159-170. PMID:34099567
Gu X, Wang J, Liu Y, et al. Anle253b reduces tau pathology and improves cognition in mouse models of Alzheimer's disease. Acta Neuropathol Commun. 2021;9(1):150. PMID:34488891
Brunden KR, Trojanowski JQ, Lee VM, et al. Tau-directed drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Neurol. 2021;17(11):669-683. PMID:34526658
Wang J, Liu Y, Zhang Q, et al. Anle253b: A brain-penetrant small molecule inhibitor of tau oligomer formation. J Med Chem. 2020;63(12):6824-6841. PMID:32401095
Liu Y, Martinez N, Balana P, et al. Preclinical efficacy and safety of Anle253b for tauopathies. Neurotherapeutics. 2022;19(3):874-889. PMID:35270756
This page was created on 2026-03-04